An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer
and activator of transcription (STAT) signalling in multiple disease states has led to an …

Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …

This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …

Janus tyrosine kinase (JAK) family of proteins have been identified as crucial proteins in
signal transduction initiated by a wide range of membrane receptors. Among the proteins in …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Traditional drug development and discovery has not kept pace with threats from emerging
and re-emerging diseases such as Ebola virus, MERS-CoV and more recently, SARS-CoV …

Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by
cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis …

Since its discovery, the Janus kinase-signal transduction and activation of transcription (JAK-
STAT) pathway has become recognized as a central mediator of widespread and varied …

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative
neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now …

Background Myelofibrosis is a chronic myeloproliferative neoplasm characterised by
splenomegaly, cytopenias, bone marrow fibrosis, and debilitating symptoms including …